Cymbalta vs. Fosamax: side effect and effectiveness comparison (a real world drug study)
Summary:
We compare the side effects and drug effectiveness of Cymbalta and Fosamax. The phase IV clinical study is created by eHealthMe based on reports (from sources including the FDA) of 389,354 people who take Cymbalta and Fosamax, and is updated regularly.
What is Cymbalta?
Cymbalta has active ingredients of duloxetine hydrochloride. It is often used in depression. eHealthMe is studying from 154,974 Cymbalta users. Check the latest studies of Cymbalta.
What is Fosamax?
Fosamax has active ingredients of alendronate sodium. It is often used in osteoporosis. eHealthMe is studying from 105,452 Fosamax users. Check the latest studies of Fosamax.
eHealthMe: drug outcomes in the real world
eHealthMe runs one of the largest post-marketing drug safety studies in the world. We study millions of patients and 5,000 more each day. Our data-driven phase IV clinical trials have been referenced on 800+ peer-reviewed medical publications including The Lancet, Mayo Clinic Proceedings, and Nature. Tools to study our phase IV findings are available to the public, anonymous and free >>>.
389,354 people who take Cymbalta and Fosamax are studied.
Drugs being compared in this study:
- Fosamax (alendronate sodium)
- Cymbalta (duloxetine hydrochloride)
Most common side effects of the drugs, overall:
Most common side effects of the drugs, in long term (1+ years) use:
Drug effectiveness:
Cymbalta:
- not at all: 5.01 %
- somewhat: 23.82 %
- moderate: 36.39 %
- high: 25.69 %
- very high: 9.09 %
Fosamax:
- not at all: 12.85 %
- somewhat: 25.28 %
- moderate: 39.25 %
- high: 17.32 %
- very high: 5.31 %
Want to compare Cymbalta with Fosamax?
- Personalize this study to your gender and age (0-99+)How to use the study?
DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.
Related publications that referenced our studies
- Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
- Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
- Stuckey BG, Sallie R, "Alendronate-induced unmasking or deterioration of coeliac disease: a case series", Osteoporosis International, 2015 Jan .
- Lee WY, Sun LM, Lin MC, Liang JA, Chang SN, Sung FC, Muo CH, Kao CH, "A higher dosage of oral alendronate will increase the subsequent cancer risk of osteoporosis patients in Taiwan: a population-based cohort study", PloS one, 2012 Dec .
Related studies
Alternative drugs to, pros and cons of:
Browse all side effects of Cymbalta:
a b c d e f g h i j k l m n o p q r s t u v w x y zBrowse all side effects of Fosamax:
a b c d e f g h i j k l m n o p q r s t u v w x y zHow the study uses the data?
The study is based on duloxetine hydrochloride and alendronate sodium (the active ingredients of Cymbalta and Fosamax, respectively). Other drugs that have the same active ingredients (e.g. generic drugs or brand names) are also considered. Dosage of drugs is not considered in the study.
Who is eHealthMe?
With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).
WARNING, DISCLAIMER, USE FOR PUBLICATION
WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.
DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.
If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.
Recent studies on eHealthMe:
- Glomerular Filtration Rate Decreased and drugs of ingredients of cisplatin - now
- Anoro Ellipta and Diclofenac drug interactions for women aged 60+ - 17 seconds ago
- Corlanor and Metformin drug interactions for women aged 40-49 - 30 seconds ago
- Biktarvy and Glomerular Filtration Rate Abnormal for Men aged 50-59 - 37 seconds ago
- Rosuvastatin Calcium and Warm Shock for Men aged 60+ - 43 seconds ago
- Rosuvastatin Calcium and Septicemic Shock for Men aged 60+ - 43 seconds ago
- Rosuvastatin Calcium and Endotoxic Shock for Men aged 60+ - 43 seconds ago
- Rosuvastatin Calcium and Bacteremic Shock for Men aged 60+ - 43 seconds ago
- Rosuvastatin Calcium and Septic Shock for Men aged 60+ - 44 seconds ago
- Could Mcp cause Septic Shock? - 46 seconds ago